Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17203540 | 0.79 | KMT2A (0.43) | KMT2AHTTNOS1PIK3CDPIK3CB | |
| SCHEMBL17255919 | 0.75 | KMT2A (0.65) | KMT2AHTTNOS1NPC1MEN1 | |
| SCHEMBL17203507 | 0.73 | PIK3CD (0.49) | KMT2AHTTPIK3CDPIK3CBPIK3CG | |
| SCHEMBL22558703 | 0.73 | KMT2A (0.41) | KMT2AHTTNPC1MEN1ALDH1A1 | |
| SCHEMBL22558858 | 0.72 | KMT2A (0.40) | KMT2AHTTPIK3CDPIK3CBPIK3CG | |
| SCHEMBL25303191 | 0.71 | HTT (0.46) | KMT2AHTTNOS1NPC1MEN1 | |
| SCHEMBL17203208 | 0.71 | NOS1 (0.46) | NOS1PIK3CDPIK3CBPIK3CGNPC1 | |
| SCHEMBL17203430 | 0.70 | KMT2A (0.44) | KMT2AHTTNOS1PIK3CDPIK3CB | |
| SCHEMBL25260124 | 0.70 | KMT2A (0.44) | KMT2AHTTNPC1MEN1ALDH1A1 | |
| SCHEMBL13968119 | 0.69 | MAP4K4 (0.54) | KMT2AHTTNPC1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134396-B1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-10112926-B2 | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| EP-3134396-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| WO-2015162456-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP4K2B, PHKG1 | KMT2A 2520/4885HTT 4793/4885NOS1 2499/4885 |
| US-10112926-B2 | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP4K2B, PHKG1 | KMT2A 2520/4885HTT 4793/4885NOS1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.